Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial

202419 citationsJournal Articlehybrid Open Access

Authors

Zhichao Jiang · Chinese Academy of Medical Sciences & Peking Union Medical College

Yibin Xie · Chinese Academy of Medical Sciences & Peking Union Medical College

Wen Zhang · Chinese Academy of Medical Sciences & Peking Union Medical College

Chunxia Du · Chinese Academy of Medical Sciences & Peking Union Medical College

Yuxin Zhong · Chinese Academy of Medical Sciences & Peking Union Medical College

Yuelu Zhu · Chinese Academy of Medical Sciences & Peking Union Medical College

Abstract

Perioperative DOS improved MPR significantly and tended to produce longer PFS compared to SOX in LAG/GEJ cancer in Asia, and might be considered as a preferred option for perioperative chemotherapy and worth further investigation.

Topics & Keywords

Gastric Cancer Management and Outcomes Esophageal Cancer Research and Treatment Gastrointestinal Tumor Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gastric Cancer

Volume 27, Issue 3, pp. 571-579

DOI: 10.1007/s10120-024-01471-z

Field-Weighted Citation Impact: 7.54